Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PEARL CHU KWONG

Allopathic & Osteopathic Physicians Dermatology Pediatric Dermatology

NPI
1043309909
CMS profile
620680
Location
JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$123,133.83

262 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 5 of 6; records 201–250 of 262 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PEARL CHU KWONG

NPI 1043309909 · CMS profile ID 620680

Allopathic & Osteopathic Physicians / Dermatology / Pediatric Dermatology

JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 6; records 201–250 of 262 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043309909?year=2020&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PEARL CHU KWONG, NPI 1043309909, CMS profile ID 620680. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 262 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043309909?year=2020&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). PEARL CHU KWONG, NPI 1043309909, CMS profile ID 620680. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 262 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043309909?year=2020&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
PEARL CHU KWONG, NPI 1043309909, CMS profile ID 620680, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 6; records 201–250 of 262 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1043309909?year=2020&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

262 matching records · $123,133.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 262 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 262.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $10.9902/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724432553 CMS
Regeneron Healthcare Solutions, Inc. $5,049.0002/20/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724432541 CMS
Regeneron Healthcare Solutions, Inc. $3,366.0002/20/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724432545 CMS
Regeneron Healthcare Solutions, Inc. $18.7702/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724432539 CMS
Regeneron Healthcare Solutions, Inc. $623.4302/17/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724432533 CMS
Regeneron Healthcare Solutions, Inc. $882.0002/17/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724432537 CMS
Regeneron Healthcare Solutions, Inc. $165.2302/15/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724432529 CMS
Galderma Laboratories, L.P. $3,150.0002/14/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860337 CMS
Regeneron Healthcare Solutions, Inc. $17.3502/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724432521 CMS
Regeneron Healthcare Solutions, Inc. $116.9502/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724432523 CMS
Regeneron Healthcare Solutions, Inc. $18.5002/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724432527 CMS
MAYNE PHARMA INC. $20.1102/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719709007 CMS
GENZYME CORPORATION $42.8702/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744169679 CMS
Lilly USA, LLC $110.7102/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728591821 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $6.5802/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737466889 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $6.3502/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737466891 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $0.2502/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737466893 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $14.2502/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737466895 CMS
Galderma Laboratories, L.P. $39.2502/08/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860309 CMS
Galderma Laboratories, L.P. $14.1302/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860313 CMS
Galderma Laboratories, L.P. $27.0202/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860319 CMS
Galderma Laboratories, L.P. $45.0302/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860323 CMS
Galderma Laboratories, L.P. $24.3002/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860327 CMS
Galderma Laboratories, L.P. $24.3102/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860332 CMS
Almirall LLC $65.1402/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728038493 CMS
Galderma Laboratories, L.P. $35.4802/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860289 CMS
Galderma Laboratories, L.P. $276.8502/07/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860295 CMS
Galderma Laboratories, L.P. $535.1502/07/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860299 CMS
Galderma Laboratories, L.P. $22.6302/07/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860305 CMS
PFIZER INC. $40.9602/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743140871 CMS
MAYNE PHARMA INC. $13.7902/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719711647 CMS
Janssen Scientific Affairs, LLC $114.1302/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719349725 CMS
GENZYME CORPORATION $89.5101/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744169665 CMS
GENZYME CORPORATION $5,049.0001/30/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744169667 CMS
GENZYME CORPORATION $661.2301/30/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744169669 CMS
GENZYME CORPORATION $19.0501/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744169673 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $2.9601/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737466887 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $10.4801/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737466885 CMS
Almirall LLC $15.9101/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728042977 CMS
Regeneron Healthcare Solutions, Inc. $13.1001/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724432517 CMS
Galderma Laboratories, L.P. $1,788.0001/21/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860283 CMS
Galderma Laboratories, L.P. $45.4701/17/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860279 CMS
Galderma Laboratories, L.P. $103.0001/16/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860261 CMS
Galderma Laboratories, L.P. $11.9001/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860267 CMS
Galderma Laboratories, L.P. $69.3201/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860270 CMS
Galderma Laboratories, L.P. $76.8901/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860275 CMS
Galderma Laboratories, L.P. $745.8501/15/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860239 CMS
Galderma Laboratories, L.P. $269.7101/15/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860247 CMS
Galderma Laboratories, L.P. $118.0001/15/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860249 CMS
Galderma Laboratories, L.P. $37.4901/15/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726860253 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $304,635.98 517
PY2020 $123,133.83 262
PY2021 $229,695.01 365
PY2022 $567,118.06 580
PY2023 $610,202.93 649
PY2024 $604,472.44 633
PY2025 $748,092.92 639

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $499,626.02 53
PY2024 Recipient $4,483.58 2
PY2024 Principal investigator $379,733.67 321
PY2023 Principal investigator $482,886.26 183
PY2022 Recipient $25,287.00 4
PY2022 Principal investigator $560,681.04 47
PY2021 Recipient $4,616.73 4
PY2021 Principal investigator $1,046,532.75 41
PY2020 Recipient $2,327.84 4
PY2020 Principal investigator $968,139.38 80
PY2019 Recipient $18,487.26 3
PY2019 Principal investigator $846,211.79 54

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

53 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $15,500.00 12/31/2025 Non-covered Recipient Entity
Suncoast Holdings Target LLC
A PHASE 3 MULTICENTER LONGTERM OPEN LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO PEDIATRIC PARTICIPANTS AGED 2 YEARS AND OLDER WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228736727
Principal investigator 1 PFIZER INC. $3,405.82 12/31/2025 Non-covered Recipient Entity
Suncoast Holdings Target LLC
PHASE 1 PKPD STUDY 6 TO 12 A STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF JAK1 IN PATIENTS AGED 6 TO 12 No dispute reported 06/30/2026 1228745259
Principal investigator 1 PFIZER INC. $2,500.00 12/16/2025 Non-covered Recipient Entity
Suncoast Skin Solutions LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228738886
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $14,500.00 12/11/2025 Non-covered Recipient Entity
Apex Clinical Research Center LLC
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata No dispute reported 06/30/2026 1252796996
Principal investigator 1 SANOFI US SERVICES INC. $17,239.00 12/10/2025 Non-covered Recipient Entity
Suncoast Holdings Target Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226103935
Principal investigator 1 ABBVIE INC. $1,470.20 12/04/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202526794
Principal investigator 1 SANOFI US SERVICES INC. $37,293.00 12/04/2025 Non-covered Recipient Entity
Suncoast Holdings Target Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226103909
Principal investigator 1 Eli Lilly and Company $9,436.00 11/25/2025 Non-covered Recipient Entity
APEX RESEARCH FOUNDATION LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187880713
Principal investigator 1 PFIZER INC. $1,736.48 11/25/2025 Non-covered Recipient Entity
Suncoast Holdings Target LLC
PHASE 1 PKPD STUDY 6 TO 12 A STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF JAK1 IN PATIENTS AGED 6 TO 12 No dispute reported 06/30/2026 1228737576
Principal investigator 1 Eli Lilly and Company $15,500.00 11/24/2025 Non-covered Recipient Entity
APEX CLINICAL TRIALS LLC SUNCOAST HOLDINGS TARGET LLC
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187876257
Principal investigator 1 PFIZER INC. $450.00 11/19/2025 Non-covered Recipient Entity
APEX Clinical Trials
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228739443
Principal investigator 1 PFIZER INC. $3,714.07 11/18/2025 Non-covered Recipient Entity
Suncoast Holdings Target LLC
PHASE 1 PKPD STUDY 6 TO 12 A STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF JAK1 IN PATIENTS AGED 6 TO 12 No dispute reported 06/30/2026 1228727205
Principal investigator 1 SANOFI US SERVICES INC. $9,744.00 10/17/2025 Non-covered Recipient Entity
Suncoast Holdings Target Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226103858
Principal investigator 1 ABBVIE INC. $2,940.40 10/09/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202513853
Principal investigator 1 Arcutis Biotherapeutics, Inc. $3,623.65 09/26/2025 Non-covered Recipient Entity
Suncoast Holding Target LLC
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163808
Principal investigator 1 SANOFI US SERVICES INC. $14,003.00 09/17/2025 Non-covered Recipient Entity
Suncoast Holdings Target Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226103821
Principal investigator 1 Eli Lilly and Company $2,945.86 09/09/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187888518
Principal investigator 1 PFIZER INC. $6,500.00 09/08/2025 Non-covered Recipient Entity
APEX Clinical Trials
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228714180
Principal investigator 1 ABBVIE INC. $3,356.20 09/03/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202508178
Principal investigator 1 SANOFI US SERVICES INC. $35,092.00 08/20/2025 Non-covered Recipient Entity
Suncoast Holdings Target Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226103791
Principal investigator 1 PFIZER INC. $450.00 08/11/2025 Non-covered Recipient Entity
APEX Clinical Trials
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228714252
Principal investigator 1 Arcutis Biotherapeutics, Inc. $3,418.15 08/07/2025 Non-covered Recipient Entity
Suncoast Holding Target LLC
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163806
Principal investigator 1 ABBVIE INC. $1,678.10 08/05/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202501640
Principal investigator 1 PFIZER INC. $1,447.00 07/16/2025 Non-covered Recipient Entity
APEX Clinical Trials
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228714178
Principal investigator 1 PFIZER INC. $15,500.00 07/11/2025 Non-covered Recipient Entity
Suncoast Holdings Target LLC
PHASE 1 PKPD STUDY 6 TO 12 A STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF JAK1 IN PATIENTS AGED 6 TO 12 No dispute reported 06/30/2026 1228782687
Principal investigator 1 ABBVIE INC. $1,678.10 07/02/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202495615
Principal investigator 1 SANOFI US SERVICES INC. $19,950.00 06/27/2025 Non-covered Recipient Entity
Suncoast Holdings Target Llc
A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants >=6 Months to <18 Years of Age With Prurigo Nodularis No dispute reported 06/30/2026 1226103724
Principal investigator 1 Incyte Corporation $10,000.00 06/05/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH, INC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240591735
Principal investigator 1 Incyte Corporation $2,500.00 06/05/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH, INC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240591738
Principal investigator 1 ABBVIE INC. $5,928.43 06/03/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202488443
Principal investigator 1 ABBVIE INC. $2,940.40 06/03/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202488445
Principal investigator 1 PFIZER INC. $2,695.00 05/30/2025 Non-covered Recipient Entity
Suncoast Skin Solutions LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228771840
Principal investigator 1 SANOFI US SERVICES INC. $19,950.00 05/12/2025 Non-covered Recipient Entity
Suncoast Holdings Target Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226103712
Principal investigator 1 Arcutis Biotherapeutics, Inc. $8,500.00 05/09/2025 Non-covered Recipient Entity
Suncoast Holding Target LLC
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163804
Principal investigator 1 ABBVIE INC. $3,697.75 05/07/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202483427
Principal investigator 1 ABBVIE INC. $2,940.40 05/06/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202481845
Principal investigator 1 Eli Lilly and Company $1,876.40 04/22/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
AN OPEN-LABEL, 24-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AND SKIN OF COLOR No dispute reported 06/30/2026 1187888874
Principal investigator 1 Eli Lilly and Company $55,305.00 04/15/2025 Non-covered Recipient Entity
APEX CLINICAL TRIALS LLC SUNCOAST HOLDINGS TARGET LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187876035
Principal investigator 1 Eli Lilly and Company $15,933.60 04/10/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187890884
Principal investigator 1 ABBVIE INC. $1,678.10 04/03/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202471409
Principal investigator 1 Eli Lilly and Company $2,417.83 03/25/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187890958
Principal investigator 1 ABBVIE INC. $1,678.10 03/06/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
M19-973 - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202457593
Principal investigator 1 UCB SA $12,101.40 03/03/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH INC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246656380
Principal investigator 1 Incyte Corporation $10.00 02/25/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH, INC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240591742
Principal investigator 1 Novartis Pharmaceuticals Corporation $87.34 02/19/2025 Non-covered Recipient Entity
SUNCOAST SKIN SOLUTIONS
Pediatric Study in children with moderate to severe Plaque Psoriasis No dispute reported 06/30/2026 1190303351
Principal investigator 1 PFIZER INC. $1,447.00 02/14/2025 Non-covered Recipient Entity
APEX Clinical Trials
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228714176
Principal investigator 1 Eli Lilly and Company $5,948.51 02/10/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187888876
Principal investigator 1 ABBVIE INC. $3,356.20 02/05/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
M19-973 - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202444955
Principal investigator 1 Eli Lilly and Company $1,940.79 01/27/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187890956
Principal investigator 1 Eli Lilly and Company $47,037.00 01/21/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187890656
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,785.60 01/14/2025 Non-covered Recipient Entity
SOLUTION THROUGH ADVANCED RESEARCH INC
Pediatric Study in children with moderate to severe Plaque Psoriasis No dispute reported 06/30/2026 1190309736
Principal investigator 1 Eli Lilly and Company $39,859.74 01/07/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187890886
Principal investigator 1 ABBVIE INC. $2,940.40 01/02/2025 Non-covered Recipient Entity
SOLUTIONS THROUGH ADVANCED RESEARCH
M19-973 - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202434726